Biocon Pharma Limited, a active public limited company, was established on 31 October 2014 in Bangalore, Karnataka, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24232KA2014PLC077036. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹1,040.15 Cr and a paid-up capital of ₹887.10 Cr.
It upholds a compliant status. Employing 526 professional, Its leadership includes Kiran Mazumdar Shaw (Director), Siddharth Mittal (Whole-Time Director), Karaikal Narayanaswamy Murali Krishnan (Director). Past directors included John Russell Fotheringham Walls, John Mccallum Marshall Shaw, Siddharth Mittal. It holds no open charges and ₹133.00 Cr settled loans. Its latest AGM occurred on 08 August 2025, with the balance sheet filed on 31 March 2025. It is based at 20Km Electronics City, Hosur Road, Bangalore - 560100, Bangalore, Karnataka, 560100.
U24232KA2014PLC077036
077036
31 October 2014
₹1,040.15 Cr
₹887.10 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Biocon Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kiran Mazumdar Shaw | Director | 31 Oct 2014 | Current |
| Siddharth Mittal | Whole-Time Director | 23 Jan 2020 | Current |
| Karaikal Narayanaswamy Murali Krishnan | Director | 13 May 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 26 Oct 2017 | Past |
| Pramod Abcsdd | Director | 31 Jul 2022 | Past |
| Pramod Abcsdd | Additional Director | 23 Jan 2020 | Past |
| Pramod Abcsdd | Company Secretary | 26 Oct 2018 | Past |
| Pramod Abcsdd | Cfo(Kmp) | 22 Oct 2020 | Past |
| Pramod Abcsdd | Additional Director | 22 Jul 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Biocon Pharma Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.3% decrease. The company also saw a substantial fall in profitability, with a 57.2% decrease in profit. The company's net worth Soared by an impressive increase of 38.03%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Biocon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹1,330,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Sep 2016 | Citi Bank N.A. | ₹133.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Biocon Pharma has a workforce of 526 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Biocon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocon Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Biocon Pharma Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records. was completed.
The activity Biocon Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore. was completed.
Soudabi Neduvanchery was appointed as a Cfo was appointed as a Cfo on 29 Aug 2024 & has been associated with this company since 1 year 4 months . was recorded as a recent event.
The activity A charge registered on 29 Sep 2016 via Charge ID 100057801 with Citi Bank N.A. was fully satisfied on 31 May 2022. was completed.
Karaikal Narayanaswamy Murali Krishnan was appointed as a Director was appointed as a Director on 13 May 2022 & has been associated with this company since 3 years 8 months . was recorded as a recent event.
Siddharth Mittal was appointed as a Whole-time director was appointed as a Whole-time director on 23 Jan 2020 & has been associated with this company since 5 years 11 months . was recorded as a recent event.
Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025..
Sen was appointed as the CFO of the company in April 2021 after Anupam Jindal stepped down. He has over 20 years of experience in financial planning, treasury, taxation and financial reporting..
The CIN of Biocon Pharma Limited is U24232KA2014PLC077036.
Biocon Pharma Limited is headquartered at 20Km Electronics City, Hosur Road, Bangalore - 560100, Bangalore, Karnataka, 560100.
Biocon Pharma Limited was incorporated on 31 October 2014.
The current directors of Biocon Pharma Limited are
The primary industry of Biocon Pharma Limited is Manufacturing.
Biocon Pharma Limited is unlisted.
The authorized capital of Biocon Pharma Limited is ₹1,040.15 Cr, and the paid-up capital is ₹887.10 Cr.
The compliance status of Biocon Pharma Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX